Letter by Clark Regarding Article, “Clinical Outcomes of Transplanted Modified Bone Marrow–Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
A small open trial that has recently appeared in Stroke,1 although primarily intended to test the safety of introducing modified adult mesenchymal stem cells (SB623) into the brain of chronic poststroke patients, has unquestionably generated considerable clinical interest. The Stanford-based authors describe striking improvements essentially never seen in untreated patients 6 months after stroke events. Motor function and other parameters are reported to have improved and been maintained, to date of writing, for ≤2 years, even in 70-year-old patients. Clearly, such a treatment outcome has the potential to revolutionize treatment of neurodegenerative diseases in general. This preliminary work certainly shows great promise and rightly attracts attention. Clearly, the reported disappearance of …